Capricor Therapeutics, Inc. (NASDAQ: CAPR)

Capricor Therapeutics Inc is a biotechnology company focused on the development and potential commercialization of cell and exosome based therapeutics for the treatment of Duchenne muscular dystrophy and other diseases with significant unmet medical need.

Capricor Therapeutics Inc generates revenue primarily through collaboration agreements milestone payments upfront fees and government grants. The company has received upfront and milestone payments from its distribution partner Nippon Shinyaku Co Ltd for Deramiocel and also receives funding from the National Institutes of Health and other agencies for its exosome based vaccine and therapeutic programs. Currently the company has no products approved for commercial sale so future revenue will depend on regulatory approval and sales of its product candidates.

Capricor Therapeutics Inc occupies a niche in the biotechnology sector focusing on cell therapy and exosome platform technologies for rare muscle diseases. Its lead candidate Deramiocel competes with exon skipping therapies such as Sarepta Therapeutics eteplirsen casimersen golodirsen and viltolarsen and with gene therapy approaches like Sarepta delandistrogene moxeparvovec. Competitive advantages include Deramiocel's mechanism targeting inflammation and fibrosis its orphan drug rare pediatric disease and RMAT designations and its partnerships with Nippon Shinyaku and the National Institutes of Health which provide development resources and potential commercialization pathways.

The company serves patients with Duchenne muscular dystrophy Becker muscular dystrophy and individuals at risk of infectious diseases such as SARS CoV 2. Its collaboration network includes Nippon Shinyaku Co Ltd as exclusive distributor in the United States and Japan the National Institute of Allergy and Infectious Diseases for its exosome based vaccine research and various academic institutions such as Johns Hopkins University and Cedars Sinai Medical Center for technology licensing and research support.